Sage Therapeutics to Present at Morgan Stanley Healthcare Conference
September 07 2017 - 4:05PM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced that Jeff Jonas, M.D., Chief Executive Officer of Sage,
will present at the Morgan Stanley Global Healthcare Conference on
Wednesday, September 13, 2017 at 8:45 a.m. ET in New York, NY.
A live webcast of the presentation can be accessed on the
investor page of Sage's website at investor.sagerx.com. A replay of
the webcast will also be archived for up to 30 days on Sage's
website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering central nervous system (CNS) disorders.
Sage has a portfolio of novel product candidates targeting critical
CNS receptor systems, GABA and NMDA. Sage's lead program,
brexanolone (SAGE-547), is in Phase 3 clinical development for
super-refractory status epilepticus, a rare and severe seizure
disorder, and for postpartum depression. Sage is developing its
next generation modulators, including SAGE-217 and SAGE-718, in
various CNS disorders. For more information, please visit
www.sagerx.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170907006533/en/
Investor Contact:Sage TherapeuticsPaul Cox,
617-299-8377paul.cox@sagerx.comorMedia Contact:Suda
Communications LLCMaureen L. Suda,
585-387-9248maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2023 to Apr 2024